Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 522


Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.

Scorsetti M, Alongi F, Fogliata A, Pentimalli S, Navarria P, Lobefalo F, Garcia-Etienne C, Clivio A, Cozzi L, Mancosu P, Nicolini G, Vanetti E, Eboli M, Rossetti C, Rubino A, Sagona A, Arcangeli S, Gatzemeier W, Masci G, Torrisi R, Testori A, Alloisio M, Santoro A, Tinterri C.

Radiat Oncol. 2012 Aug 28;7:145. doi: 10.1186/1748-717X-7-145.


Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity.

Fiorentino A, Mazzola R, Ricchetti F, Giaj Levra N, Fersino S, Naccarato S, Sicignano G, Ruggieri R, Di Paola G, Massocco A, Gori S, Alongi F.

Cancer Radiother. 2015 Aug;19(5):289-94. doi: 10.1016/j.canrad.2015.02.013. Epub 2015 Jul 20.


Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results.

De Rose F, Fogliata A, Franceschini D, Navarria P, Villa E, Iftode C, D'Agostino G, Cozzi L, Lobefalo F, Mancosu P, Tomatis S, Scorsetti M.

Radiat Oncol. 2016 Sep 17;11(1):120. doi: 10.1186/s13014-016-0701-z.


Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.

Cante D, Rosa La Porta M, Casanova-Borca V, Sciacero P, Girelli G, Pasquino M, Franco P, Ozzello F.

Breast J. 2011 Nov-Dec;17(6):586-93. doi: 10.1111/j.1524-4741.2011.01159.x. Epub 2011 Sep 21.


Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.

Freedman GM, Anderson PR, Goldstein LJ, Ma CM, Li J, Swaby RF, Litwin S, Watkins-Bruner D, Sigurdson ER, Morrow M.

Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):347-53. Epub 2007 Mar 26.


Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors.

Ciammella P, Podgornii A, Galeandro M, Micera R, Ramundo D, Palmieri T, Cagni E, Iotti C.

Radiat Oncol. 2014 Apr 24;9:97. doi: 10.1186/1748-717X-9-97.


[Preliminary results of whole breast helical tomotherapy with simultaneous integrated boost in the adjuvant treatment of breast cancer].

Liem X, Chira C, Fourquet A, Campana F, Peurien D, Fournier-Bidoz N, Kirova YM.

Cancer Radiother. 2014 Jan;18(1):15-22. doi: 10.1016/j.canrad.2013.07.149. Epub 2013 Dec 6. French.


Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series.

De Rose F, Fogliata A, Franceschini D, Iftode C, Torrisi R, Masci G, Sagona A, Tinterri C, Testori A, Gatzemeier W, Fernandes B, Rahal D, Cozzi L, Santoro A, Scorsetti M.

Br J Radiol. 2018 May;91(1085):20170634. doi: 10.1259/bjr.20170634. Epub 2018 Mar 20.


A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects.

Guenzi M, Vagge S, Azinwi NC, D'Alonzo A, Belgioia L, Garelli S, Gusinu M, Corvò R.

Radiat Oncol. 2010 Nov 22;5:111. doi: 10.1186/1748-717X-5-111.


Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives.

Alford SL, Prassas GN, Vogelesang CR, Leggett HJ, Hamilton CS.

J Med Imaging Radiat Oncol. 2013 Apr;57(2):222-9. doi: 10.1111/j.1754-9485.2012.02473.x. Epub 2013 Mar 26.


Skin toxicity and cosmesis after hypofractionated whole breast irradiation for early breast cancer.

Saksornchai K, Rojpornpradit P, Shotelersak K, Lertbutsayanukul C, Chakkabat C, Raiyawa T.

J Med Assoc Thai. 2012 Feb;95(2):229-40.


Accelerated hypofractionated radiotherapy as adjuvant regimen after conserving surgery for early breast cancer: interim report of toxicity after a minimum follow up of 3 years.

Pinnarò P, Soriani A, Landoni V, Giordano C, Papale M, Marsella A, Marucci L, Arcangeli G, Strigari L.

J Exp Clin Cancer Res. 2010 Jan 25;29:9. doi: 10.1186/1756-9966-29-9.


Weekly concomitant boost in adjuvant radiotherapy for patients with early breast cancer: preliminary results on feasibility.

Corvò R, Giudici S, Maggio F, Bevegni M, Sampietro C, Lucido MR, Orsatti M.

Tumori. 2008 Sep-Oct;94(5):706-11.


Intraoperative radiotherapy (IORT) as a boost in patients with early-stage breast cancer -- acute toxicity.

Kraus-Tiefenbacher U, Bauer L, Kehrer T, Hermann B, Melchert F, Wenz F.

Onkologie. 2006 Mar;29(3):77-82. Epub 2006 Mar 3.


Adjuvant hypofractionated radiotherapy with weekly concomitant boost for women with early breast cancer: the clinical experience at Genoa university.

Corvò R, Ricchetti F, Doino D, Torielli P, Agostinelli S, Cavagnetto F, Giannelli F, D'Alonzo A, Vagge S, Belgioia L, Guenzi M.

Anticancer Res. 2010 Nov;30(11):4749-53.


Phase 2 trial of accelerated, hypofractionated whole-breast irradiation of 39 Gy in 13 fractions followed by a tumor bed boost sequentially delivering 9 Gy in 3 fractions in early-stage breast cancer.

Kim JY, Jung SY, Lee S, Kang HS, Lee ES, Park IH, Lee KS, Ro J, Lee NK, Shin KH.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1037-42. doi: 10.1016/j.ijrobp.2013.09.019.


Factors of influence on acute skin toxicity of breast cancer patients treated with standard three-dimensional conformal radiotherapy (3D-CRT) after breast conserving surgery (BCS).

Kraus-Tiefenbacher U, Sfintizky A, Welzel G, Simeonova A, Sperk E, Siebenlist K, Mai S, Wenz F.

Radiat Oncol. 2012 Dec 18;7:217. doi: 10.1186/1748-717X-7-217.


Hypofractionated radiotherapy for breast cancers--preliminary results from a tertiary care center in eastern India.

Nandi M, Mahata A, Mallick I, Achari R, Chatterjee S.

Asian Pac J Cancer Prev. 2014;15(6):2505-10.


5-year results of pulsed dose rate brachytherapy applied as a boost after breast-conserving therapy in patients at high risk for local recurrence from breast cancer.

Harms W, Krempien R, Hensley FW, Berns C, Fritz P, Wannenmacher M.

Strahlenther Onkol. 2002 Nov;178(11):607-14.


Supplemental Content

Support Center